For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Healios Continues to Seek MultiStem Approval despite Trial Miss: CEO
May 24, 2022
- Tohoku Univ., Drug Makers, MICIN to Jointly Collect Lifestyle Data with Wearable
May 24, 2022
- OrphanPacific Grabs Japan Rights to Immedica Drug for Urea Cycle Disorder
May 24, 2022
- Shionogi President Teshirogi to Also Become Chairman from July
May 24, 2022
- First Wipe Drug for Axillary Hyperhidrosis Now Available in Japan
May 24, 2022
- Healios’ Sakigake Cell Therapy Misses Goal in Ischemic Stroke
May 23, 2022
- US Court Dismisses Astellas Claim over Lexiscan Patent
May 23, 2022
- Movicol High-Dose Version Launched for Constipation: EA Pharma
May 23, 2022
- Fostering Biopharma Startups Is Vital to New Drug Development in Japan: IQVIA
May 20, 2022
- Opdivo Expands Indication in Taiwan for RCC in Combo with Cabozantinib
May 20, 2022
- A Few More Years before Human Trials Can Start for Potential Diabetes Cure, Novo CSO Says
May 20, 2022
- AbbVie’s Japan Sales Sag 13% in 2021 as Off-Year Price Cuts, Synagis Return Weigh
May 19, 2022
- Sosei, Kallyope Partner in R&D of GPCR Targets for GI Drug Discovery
May 18, 2022
- Ricoh to Venture into mRNA Drug Discovery Support Biz with Elixirgen Buy
May 18, 2022
- Argenx CEO Sees Big Potential for Vyvgart with 100-Plus Diseases Driven by IgGs; Analysts Peg Peak Sales at US$5-10 Billion
May 18, 2022
- AstraZeneca Ranks Third in Japan Sales Ranking with 12.1% Growth, Good Start in Q1 Too
May 18, 2022
- 8 Japan Drug Majors’ Combined Sales Rise 10.2% in FY2021 on Global Brands, Strong Offshore Presence Is Key to Further Growth
May 17, 2022
- Minomycin Stockout Looms in Mid-June over Manufacturing Delays: Pfizer
May 17, 2022
- Shionogi Grabs Europe and Asia Rights to F2G’s Antifungal Drug
May 17, 2022
- Shionogi’s COVID-19 Vaccine Enters PII/III with Japanese Adolescents
May 17, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…